Restricted accessOtherFirst published online 1998-7
Comments on Appendix C of the National Institutes of Health Response to the Petition of the American Anti-Vivisection Society to Prohibit the Use of Animals in the Production of Monoclonal Antibodies
MarxU., EmbletonM.J., FischerR., GruberF.P., HanssonU., HeuerJ., de LeeuwW., LogtenbergT., MerzW., PortetelleD., RometteJ-L., & StraughanD. (1997). Monoclonal antibody production. The report and recommendations of ECVAM workshop 23.ATLA25, 121–137.
2.
FalkenbergF.W., HengelageT., KraneM., BartelsI., AlbrechtA., HoltmeierN., & WüthrichM. (1993). A simple and inexpensive high density dialysis tubing cell culture system for the in vitro production of monoclonal antibodies in high concentrations.Journal of Immunological Methods165, 193–206.
3.
LowreyD., MurphyS., and GoffeR.A. (1994). A comparison of monoclonal antibody productivity in different hollow fibre bioreactors.Journal of Biotechnology36, 35–38.
4.
FalkenbergF.W., WeichertH., KraneM., BartelsI., PalmeM., NagelsH.O., and FiebigH. (1995). In vitro production of monoclonal antibodies in high concentrations in a new and easy to handle modular minifermentor.Journal of Immunological Methods179, 13–29.
5.
JacksonL.R., TrudelL.J., FoxJ.G., and LipmanN.S. (1996). Evaluation of hollow fibre bioreactors as an alternative to murine ascites production for small scale monoclonal antibody production.Journal of Immunological Methods189, 217–231.
6.
SchacterE. (1989). Serum-free medium for bulk culture of hybridoma cells and the preparation of monoclonal antibodies.Trends in Biotechnology7, 248–253.
7.
FikeR.M., JaymeD.W., and WeissS.A. (1991). Monoclonal antibody enhancement in protein-free and serum-supplemented hybridoma culture media.American Biotechnology Laboratory9, 40–42.
8.
ChuaF., OhS., YapM., and TeaW. (1994). Enhanced IgG production in cRDF media with and without serum.Journal of Immunological Methods167, 109–119.
9.
StollT., ChappazA., von StockarU., and MarisonI.W. (1997). Effects of culture conditions on the production and quality of monoclonal IgA.Enzyme and Microbial Technology21, 203–211.
10.
StollT., MohlethalerK., von StockarU., and MarisonI.W. (1996). Systematic improvement of a chemically-defined protein-free medium for hybridoma growth and monoclonal antibody production.Journal of Biotechnology45, 111–123.
11.
LeibigerH., HansenA., SchoenherrG., SeifertM., WüstnerD., StiglerR., and MarxU. (1995). Glycosylation analysis of a polyreactive human monoclonal IgG antibody derived from a human-mouse heterohybridoma.Molecular Immunology32, 595–602.
12.
HendriksenC., RozingJ., van der KampM., & de LeeuwW. (1996). The production of monoclonal antibodies: are animals still needed?ATLA24, 109–110.
13.
RoggenbuckD., MarxU., KiessigS.T., SchoenherrG., JahnS., and PorstmannT. (1994). Purification and immunochemical characterisation of a natural human polyreactive monoclonal IgM antibody.Journal of Immunological Methods167, 207–218.
14.
StollT., RuffieuxP-A., LüllauE., von StockarU., and MarisonI.W. (1995). Characterization of monoclonal IgA production and activity in hollow fibre and fluidized-bed reactors.Progress in Biotechnology11, 608–614.
15.
StollT., PerregauxC., von StockarU., and MarisonI.W. (1995). Production of immunoglobulin A in different reactor configurations.Cytotechnology17, 53–63.
16.
LüllauE., HeyseS., VogelH., MarisonI.W., von StockarU., KraehenbuhlJ-P., & CorthésyB. (1996). Antigen binding properties of purified IgA and reconstituted secretory IgA antibodies.Journal of Biological Chemistry271, 16,300–16,309.
